We have conducted more than 50 clinical trials as we strive to bring important new medicines to patients with diseases like ALS, heart failure, and SMA.
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. CytokineticMore >>
SOUTH SAN FRANCISCO, Calif. , April 24, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented by John Day , M.D., Ph.D., Professor of Neurology and
SOUTH SAN FRANCISCO, Calif. , April 12, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report first quarter results on April 26, 2018 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
SOUTH SAN FRANCISCO, Calif. , March 05, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) announced today that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the following investor conferences: Cowen and Company 38 th
SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Cytokinetics , Incorporated (Nasdaq:CYTK) today announced that it is joining the global initiative to raise awareness of Rare Disease Day®, an international campaign led by the European Organisation for Rare Diseases (EURORDIS) and the
